The Pharma Data

SEPTEMBER 11, 2021

Boehringer Ingelheim believes Twist’s ability to generate potent, diverse therapeutic antibodies by mining its comprehensive libraries, combined with our extensive capabilities and experience in drug discovery and development, will enable us to deliver breakthrough opportunities to patients,” said Clive R. About Twist Bioscience Corporation.

Antibody 52

Antibody DNA Containment Manufacturing 52

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. million price point per dose.

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

Drug Discovery World

FEBRUARY 12, 2024

Leslie Orne, President and CEO, Trinity Life Sciences “AI and ML will play an increasingly important role in the clinical development and commercialisation of cell and gene therapies, which are typically targeted to small patient populations.

Genome 139

Genome Genomics Life Science Gene Therapy 139

Drug Discovery World

JUNE 22, 2023

This has been demonstrated to be an effective way to improve AAV delivery, to increase the breadth of expression in pre-clinical models, and to shield AAVs from neutralising antibodies. “We The post Evox Therapeutics acquires exosome AAV technology from Codiak appeared first on Drug Discovery World (DDW).

Gene Therapy 52

Gene Therapy Gene Editing Drug Delivery Gene 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. These animals have been used as a key tool in functional genomics to generate models for human diseases and to validate new drugs.

Genetics 130

Genetics DNA Antibody Genome 130

Pharmaceutical Technology

FEBRUARY 14, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin 1, which are now well established in the industry.

In-Vivo 130

In-Vivo DNA Antibody Gene 130

Pharmaceutical Technology

MARCH 9, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

In-Vivo 130

In-Vivo Antibody Genetics Gene 130

Drug Discovery World

NOVEMBER 27, 2023

As the significance of large molecules continues to broaden across diverse modalities, emphasis on bispecific and multispecific antibodies to treat various disorders such as rheumatologic diseases, cancer, diabetes, anaemia, and infectious diseases becomes paramount. References Mistry RK, Kelsall E, Sou SN, et al.

Production 59

Production Engineer Gene Editing Gene 59

pharmaphorum

MARCH 24, 2022

The examples remain few and far between, however, as in recent decades the pharma industry has turned its attention to synthetic molecules and biologics like antibodies. The platform uses an artificial intelligence (AI) algorithm to zero in on the genes encoding natural products based on their computationally predicted human target.

Medicine 102

Medicine Genome Genomics Engineer 102

Pharmaceutical Technology

FEBRUARY 3, 2023

The field of genomic medicine has reached a true turning point. With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more.

Genome 244

Genome Genomics Medicine Gene Therapy 244

Drug Discovery World

JULY 10, 2023

Artificial intelligence (AI), gene editing, synthetic biology and more, are beginning to prove their usefulness in drug design and development, taking therapies away from the one-size-fits-all approach, towards more definable targets that operate more effectively. There are myriad ways that this is being enabled.

Gene Therapy 52

Gene Therapy Gene Scientist Gene Editing 52

Pharmaceutical Technology

DECEMBER 9, 2022

In regards to the latter, notable examples include the acquisition of Cergentis, a genomics-focused biotechnology company based in the Netherlands. The deal allows the company to provide proprietary technology and knowledge steeped in fast-evolving genomic techniques that support effective decision-making and R&D program design.

Development 130

Development Production Manufacturing Vaccination 130

Drug Discovery World

MARCH 26, 2024

For example, progress made in developing gene mutant-specific inhibitors, antibody-drug conjugates (ADC), or cellular therapies. OR: The presentations at ESMO TAT 2024 highlighted our advances in targeted and more personalised anti-tumour therapies.

RNA 64

RNA In-Vivo In-Vitro DNA 64

Cloudbyz

MARCH 6, 2024

For example, monoclonal antibodies, a type of biologic, can selectively bind to specific targets such as proteins or cells involved in disease processes, thereby modulating immune responses or inhibiting disease progression. One of the key features of biologics is their ability to mimic or augment natural biological processes within the body.

Gene 74

Gene Immune Response Manufacturing Gene Therapy 74

Drug Discovery World

MAY 25, 2023

Gyros Protein Technologies: Gyrolab Generic Cyno Anti-Drug Antibodies (ADA) Kit Reagents The kit reagents are for the detection of circulating immune complexes of human IgG with cyno anti-human IgG.

Production 52

Production Reagent DNA Drugs 52

XTalks

JUNE 16, 2023

Cetuximab, an anti-epidermal growth factor receptor (anti-EGFR) antibody with FDA approval for metastatic colorectal cancer, is effective in conjunction with encorafenib. A negative result from a plasma specimen does not rule out genomic findings in a patient’s tumor. ” What is FoundationOne Liquid CDx? .

FDA Approval 97

FDA Approval Genome Genomics DNA 97

pharmaphorum

JANUARY 24, 2023

The cost of testing per human genome in 2006 was approximately $14 million , and in less than two decades, an average consumer-purchased genetic test costs $100. The same is becoming true for the healthcare industry, and one of the first major breakthroughs in the area was the 100,000 Genomes Project.

Genetics 95

Genetics Drugs Genome Project Biobanking 95

Drug Discovery World

OCTOBER 16, 2023

Alchemab, on the other hand, has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics by analysis of patient antibody repertoires, drawing from the expertise in Cambridge to progress the company’s mission to build a broad pipeline of protective therapeutics for hard-to-treat diseases.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Drug Discovery World

MARCH 13, 2024

In 2019 he was part of a research team which discovered humanised antibody, PRL3-zumab, was effective at shrinking PRL3 over-expressing tumours, and which has since been approved for Phase II clinical trials in Singapore, the US and China. In our study, we identified TOX2 as an important gene over-expressed and critical for NKTL survival.

Life Science 69

Life Science Genome Genomics Research 69

XTalks

NOVEMBER 30, 2023

More Investigational Therapies for HIV Are on the Way American Gene Technologies, a pioneering biotech company headquartered in Rockville, Maryland, has released promising results from its Phase I trial of AGT103-T, a gene therapy designed for individuals with chronic HIV disease. In November 2023, Hookipa Pharma Inc.,

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

Pharmaceutical Technology

MAY 8, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Genetics 130

Genetics DNA Genetic Engineering Antibody 130

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Gene splicing using nucleases. They are engineered to cut specific genomic targets in order to modify the expression of single genes and proteins.

Gene Splicing 130

Gene Splicing Gene Recombinant DNA Technology DNA 130

The Pharma Data

JANUARY 24, 2021

. “We are excited to welcome Chris, a highly regarded drug developer and team builder who brings to Notch great depth of experience and expertise in development of cell therapies, gene editing, and cell engineering spanning discovery through IND,” said David Main , President and Chief Executive Officer of Notch.

Engineer 52

Engineer Gene Editing Genome Genomics 52

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) to begin a Phase I clinical trial of hAd5-COVID-19, the company’s novel COVID-19 vaccine candidate that targets both the inner nucleocapsid (N), engineered to activate T cells, and outer spike (S) protein, engineered to activate antibodies against the coronavirus (SARS-CoV-2).

Antibody 52

Antibody Vaccination Vaccine Trials 52

FDA Law Blog

NOVEMBER 2, 2023

While on the surface this may not seem like major advance for the field, this could be a game changer for the gene therapy space. These meetings have a question-and-answer format to provide clarity to sponsors about the particular topics at hand.

Medicine 59

Medicine Gene Therapy Gene Production 59

The Pharma Data

APRIL 8, 2021

Advances in Drug Delivery (Session #ADT08), with a discussion on the advances and innovations fueling the development of the next generation of antibody drug conjugates. The introduction of AZD8853, a novel antibody targeting GDF15 for tumours refractory to immunotherapy treatment.

DNA 52

DNA Medicine Genome Genomics 52

pharmaphorum

JULY 14, 2022

The antibody-drug conjugate (ADC) was turned down by NICE in draft guidance published earlier this year, leading to concerns of a disparity in access to the drug as the Scottish Medicines Consortium (SMC) had already cleared its use. NICE estimates that around 2,800 people are eligible for treatment with Piqray plus fulvestrant.

Drugs 99

Drugs Hormones Genome Genomics 99

Delveinsight

AUGUST 27, 2020

As observed in 45 younger adults, the middle dose of the vaccine triggered the production of neutralizing antibodies against SARS-CoV-2, the virus, which causes COVID-19 , in 10 patients aged 56 to 70 and 10 patients over 71. Freenome secures USD 270 Million to boost its colorectal cancer blood test.

Vaccination 53

Vaccination Vaccine Research Trials 53

XTalks

MARCH 28, 2024

Furthermore, the introduction of multi-targeted kinase inhibitors and monoclonal antibodies is also being examined as a possible form of therapy. Gene Editing and CAR T-Cell Therapy Genetic engineering technologies, such as CRISPR-Cas9, are providing newer potential avenues for cancer treatment.

Gene Editing 59

Gene Editing Life Science Clinical Trials Clinical Trials 59

The Pharma Data

MARCH 3, 2021

Christopher Corsico, Senior Vice President Development, GSK said: “We want to thank the patients who participated in this study and the NIH for investing in the ACTIV trial to evaluate the four monoclonal antibodies, as it recognises the need for differentiated treatments, especially as new variants emerge globally.

Trials 52

Trials Antibody Vaccination Vaccine 52

Pharmaceutical Technology

JUNE 4, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Gene 262

Gene Gene Therapy Genetics DNA 262

Pharmaceutical Technology

DECEMBER 22, 2022

The main focus is the antibody-drug conjugate (ADC ), Enhertu (trastuzumab deruxtecan), which had already achieved regulatory approval as a second-line therapy for metastatic or recurrent HER2-positive breast cancer, as well as HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Insulin 130

Insulin Production Development Genetics 130

The Pharma Data

NOVEMBER 3, 2020

LogicBio’s proprietary genome editing technology platform, GeneRide, enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. LogicBio is also developing a Next Generation Capsid platform for use in gene editing and gene therapies.

Clinical Trials 52

Clinical Trials Clinical Trials Gene Editing Genome 52

Drug Discovery World

MAY 11, 2023

Kerstin Pohl , Senior Global Marketing Manager, Gene Therapy & Nucleic Acid at SCIEX, looks at the application of liquid chromatography-mass spectrometry for analysing host cell proteins. Gene-based therapeutics and vaccines hold immense potential for more efficient and personalised treatment and prevention of complex diseases.

Production 52

Production Gene Protein Vaccination 52

Drug Discovery World

JANUARY 27, 2023

The drug is approved as monotherapy for adult patients who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.

Drugs 52

Drugs Engineer Antibody Development 52

pharmaphorum

NOVEMBER 12, 2020

UCB has made a new foray into the gene therapy space, buying fellow Belgium-based company Handl to get control of its adeno-associated virus (AAV) capsid delivery platform and two research programmes in neurodegenerative diseases. The post UCB revs up its gene therapy drive with Handl acquisition appeared first on.

Gene Therapy 52

Gene Therapy Gene Manufacturing Contract Manufacturing 52

The Pharma Data

NOVEMBER 5, 2020

Velders is presently chairman of HollandBIO, the association of Dutch biotech companies, and provides years of experience, specifically in the cell and gene therapy areas. Deep Genomics – Toronto-based Deep Genomics appointed Amanda Kay to the newly-created role of chief business officer.

Genome 40

Genome Genomics Medicine Life Science 40